|
Current issue
Archive
Online First
About the journal
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Special Issues
Instructions for authors
Publication charge
Editorial System
Submit your Manuscript
|
3/2010
vol. 9 abstract:
Review paper
What’s new in the treatment of female pelvic inflammatory disease?
Grzegorz Stachowiak
,
Tomasz Pertyński
Przegląd Menopauzalny 2010; 3: 140–144
Online publish date: 2010/06/16
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Pelvic inflammatory disease (PID) is a large group of inflammatory polymicrobial illnesses of female genital organs, mostly caused by Chlamydia trachomatis and Neisseria gonorrhoeae. When poorly treated it leads to
some serious distant side effects e.g. impaired fertility. Quinolones play an important role in the treatment of PID, whereas newly introduced moxifloxacin is characterized by high therapeutic efficacy and safety. keywords:
PID, Chlamydia, inflammation, pelvis minor, moxifloxacin |